All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | In contrast with other [[Hyperglycemia|anti-hyperglycemic]] [[diabetes medication]]s, SGLT2 inhibitors enhance, rather than suppress, [[gluconeogenesis]] and [[ketogenesis]]. Because SGLT2 inhibitors activate [[sirtuin 1]] (and thus [[PPARGC1A|PGC-1α]] and [[FGF21]]), they are more [[Cardioprotection|cardioprotective]] than the other medications used to treat [[diabetes]]. |
| h Japanese (ja) | 他の[[Hyperglycemia/ja|抗高血糖]][[diabetes medication/ja|糖尿病医薬品]]とは対照的に、SGLT2阻害薬は[[gluconeogenesis/ja|糖新生]]および[[ketogenesis/ja|ケト新生]]を抑制するのではなく、むしろ亢進させる。SGLT2阻害薬は[[sirtuin 1/ja|サーチュイン1]]（ひいては[[PPARGC1A/ja|PGC-1α]]と[[FGF21/ja|FGF21]]）を活性化するため、[[diabetes/ja|糖尿病]]の治療に用いられる他の医薬品よりも[[Cardioprotection/ja|心臓保護]]効果が高い。 |